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1. Introduction 
The regulation of the immunoglobulin heavy chain (Igh) alternative RNA processing has 
served as a model system for revealing the competition between cis and trans-acting RNA 
factors influencing splicing and polyadenylation, reviewed in  (Peterson 2007) and (Borghesi 
and Milcarek 2006). This review will explore recent studies on the role of transcription 
elongation factors in the super elongation complex (SEC) including ELL2 (eleven-nineteen 
lysine rich leukemia factor) on driving poly(A) site choice. Elongation factors impel high 
levels of Igh mRNA production and alternative processing at the promoter proximal, 
secretory-specific poly(A) site (sec) in plasma cells by enhancing RNA polymerase II 
modifications and downstream events. The sec poly(A) site, essentially hidden in B cells, is 
found by SEC factors in plasma cells. 
Most mRNAs have a poly(A) tail and it has been estimated that up to 20% of the human 
genes may be arranged with a competition of splicing and polyadenylation sites as seen in 
the Igh (Tian, Pan et al. 2007; Rigo and Martinson 2008). Numerous genes contain multiple 
poly(A) sites (Tian, Hu et al. 2005); many subject to regulation (Edwalds-Gilbert, Veraldi et 
al. 1997) and (Lutz and Moreira 2011). Advancing developmental stage is generally 
correlated with use of promoter distal poly(A) sites (Ji, Lee et al. 2009; Ji and Tian 2009). Yet 
the opposite situation applies as B-cells terminally differentiate into plasma cells; elongation 
factors may hold the key to understanding this apparent paradox. 
Transcriptional pausing and subsequent elongation are emerging as important check points 
for gene regulation. Phosphorylation of the carboxyl-terminal domain of RNAP-II by 
initiation and elongation factors directs the correct associations to ultimately drive mature 
mRNA output. The SEC, composed of nine proteins including pTEFb and ELL (see key), 
kick starts elongation by facilitating the phosphorylation of both the negative acting factors 
that have stalled the polymerase and polymerase itself. The mPAF is recruited by the action 
of the pTEFb through phosphorylation of the serine-2 of the RNA polymerase carboxyl-
terminal domain heptad repeat; mPAF  brings along with it the polyadenylation factors. The 
factors that polyadenylate mRNA are more strongly associated with the polymerase 
transcription complex on highly active promoters and/ or through up-regulation of the 
polyadenylation and elongation factors, especially CstF (cleavage stimulatory factor), 
pTEFb, and ELL2. Polymerases deficient in the appropriate factors may transit the gene, but 
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if these pauci-polymerases proceed, they lack sufficient concentrations of factors to 
efficiently process the nascent RNA. Information from the literature on the linkages between 
elongation and alternative processing as well as TAR:TAT mediated RNA output and 
pTEFb interactions in HIV infected T-cells inform the search for understanding the 
mechanisms operative in the Igh locus.  
 
Frequently used abbreviations:  CPSF, Cleavage Polyadenylation Specificity Factor with 
subunits of 160, 100, 73 & 30 kDa; CstF, Cleavage stimulatory factor. Subunits of 77, 64 and 50 
kDa; CTD, the carboxyl-terminal domain of eukaryotic RNA polymerase II;  ELL2, eleven-
nineteen lysine rich leukemia factor, RNA polymerase elongation factor 2, similar but not identical 
to ELL1; Igh, immunoglobulin heavy chain;  mPAF, Human/ mammalian analog of yeast 
complex, polymerase II associated factors that coordinate setting of histone marks associated with 
active transcription;   Mediator, Large, variable complex of proteins associated with DNA-bound 
transcription factors aiding RNAP-II binding to transcription start site. Composition may depend 
on promoter; pTEFb, positive transcription elongation factor b, composed of cyclin T and cdk9; 
RNAP-II, RNA Polymerase II of eukaryotic cells, composed of multiple subunits; SEC, super 
elongation complex for transcription elongation; Sec:mb, Ratio of secretory-specific 
polyadenylated to M1 spliced Igh mRNA; >20:1 in plasma cells;  SR proteins, Serine and 
Arginine rich proteins that tend to enhance splicing (eg. SF2/ASF) of the pre-mRNA exons to 
which they bind. In contrast, SRp20 seems to suppress exon inclusion;  U1A, Protein A (35 kDa) 
found with the U1 small nuclear RNP (U1 snRNP). 
2. Igh and plasma cell gene regulation, an RNA processing problem 
The mature B-cell has an exquisitely specific antigen receptor, the membrane form of the 
Immunoglobulin of the mu or delta type, paired with Ig light chain, expressed on its surface. 
The V region of the Ig is the result of a series of gene rearrangements generating specificity 
in the development of that B cell. This B cell can be activated by antigen association directly 
or be assisted in its differentiation by T-cells to start to secrete the Ig in the terminally 
differentiated B cell, i.e. the plasma cell. There are seven immunoglobulin heavy chain genes 
(Igh)  in mice. The mouse heavy-chain genes (isotypes) are named mu, delta, gamma 1,  
gamma 2a,  gamma 2b and gamma 3, and alpha; they are clustered together in an array on 
the chromosome in that order. The name of the heavy chain designates the name of the 
H2:L2 molecule; for example µ2:L2, i.e. mu heavy chains plus light chains, are designated 
IgM while and 2:L2 are called IgD. The heavy chains encode secreted proteins of 
approximately 55,000 kDa, with mu producing the largest H chain. The light chains (kappa 
or lambda) produce approximately 25,000 kDa proteins and the genes undergo no 
alternative RNA processing.  Each Igh gene has the capability to produce both membrane-
specific and secreted forms of the protein, as encoded in the alternatively processed heavy 
chain mRNAs. Plasma cells express only one of the Igh isotypes as a secreted protein. 
Blimp-1, (B-lymphocyte inducer of maturation) a transcription repressor, turns off a number 
of early B-cell transcription factors like pax-5 and bcl-6 while it indirectly activates 
production of the secreted form of the Igh mRNA and a family of gene products leading to 
plasma cell terminal differentiation. Among the blimp-inducible genes are ELL2 and EAF2 
(Kuo and Calame 2004; Shaffer, Shapiro-Shelef et al. 2004); these are two transcription 
elongation factors previously isolated in transcription studies. Activation of the blimp-1 
gene  occurs both in T-dependent and T-independent pathways for B-cell development, as 
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Cytokines, BCR engagement, CD40 
IRF4 high  IRF4 low 
↓ ↓  ↓ ↓ 
ELL2, EAF2 ← Blimp-1 ↔ Inhibit ↔ Bcl-6 AID, IRF8 
 
↓ 
↓   
↓ 
 
↓ Xbp-1  ↓  
Plasma cell program  Germinal center program 
High Ig secretion and mRNA  Ig membrane, low mRNA 
Fig. 1. A proposed schema of plasma cell versus germinal center cell development adapted 
from (Lu 2008) and (Sciammas, Shaffer et al. 2006) with roles for ELL2 and EAF2 added. 
Blimp-1 and Bcl-6 have been shown to inhibit each other (Shaffer, Yu et al. 2000). Xbp-1 is 
also involved in the unfolded protein response in plasma cells (Shaffer, Shapiro-Shelef et al. 
2004). 
recently reviewed (Martins and Calame 2008). Blimp-1 is low or absent in memory B-cells; 
meanwhile IRF-4 levels are key to the activated/ memory/ plasma cell transition; the role 
for each gene, as well as Xbp-1, is still under active investigation, see review (Martins and 
Calame 2008); one synthesis of all the information is presented in (Lu 2008). It is also notable 
that ELL2 expression is influenced directly by expression of IRF4, a transcription factor that 
modulates plasma cell differentiation; IRF4 was found bound to the ELL2 promoter by 
chromatin immune-precipitation studies (Shaffer, Emre et al. 2008).  
The Igh transcripts of any isotype are subject to alternative RNA processing, summarized in 
(Borghesi and Milcarek 2006) and (Peterson 2007) and diagrammed in Figure 2. The various 
Igh genes have different numbers of CH regions so the last secretory exon is labeled CH4 in 
the mu Igh or CH3 in the gamma genes. When the secretory specific poly(A) site is used, the 
pre-mRNA is cleaved so that splicing between the site embedded in the last secretory-
specific exon and M1 does not occur. This is the preferred but not exclusive mode in plasma 
cells. The spacing between the weak M1 splicing and sec-specific poly (A) sites in the 
various Igh genes is highly conserved at ~300 nts. When the splice in CH3 (γ) or CH4 (µ) is  
 
 
Fig. 2. The Igh chain. Mouse IgG2a heavy chain gene is shown with sites for primers used 
for QPCR (Shell, Martincic et al. 2007). The identical IgG2a gene is expressed in the A20 
mouse B cells and AxJ plasma cells; the VH used is a single copy gene. The two mRNAs, 
secretory (sec) and membrane-specific (mb) are shown. 
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completed to M1, the secretory specific poly(A) site is removed from the pre-mRNA and 
unavailable and the mb poly(A) site is used. This is the predominant pathway in mature and 
memory B-cells. The sec poly(A) and splice to M1 are therefore mutually exclusive in any 
one transcript, while within the population of RNAs the sec:mb ratio is ~1:1 in B-cells and in 
plasma cells sec:mb is >20:1. The tendency to use the first poly(A) site in plasma cell 
development for the Igh gene reverses the trend seen in many developmentally regulated 
genes where it is the downstream site not the upstream site favored as development 
proceeds, perhaps caused by a weakening of mRNA polyadenylation activity (Ji, Lee et al. 
2009). ELL2 may be induced to reverse this trend in plasma cells and thus alleviating a 
transcriptional pause may lead to alternative mRNA processing. We will explore the 
regulation of the alternative processing of the Igh RNA in the course of this review. 
3. Differential expression of factors in a number of pathways seen between B 
cells and plasma cells 
The entire ~11 kb gamma 2a or 2b Igh gene is transcribed ~2kb past the membrane poly(A) 
site regardless of which poly(A) site is used; this occurs in both B-cells and plasma cells 
(Flaspohler and Milcarek. 1990; Flaspohler and Milcarek 1992; Flaspohler, Boczkowski et al. 
1995). The plasma cell phenotype dominates over that seen in the mature/memory B-cell 
when somatic cell hybrids were created and influences the nuclear versus cytoplasmic 
accumulation of many RNAs; Igh chain is the most profoundly affected. Igh protein levels 
are directly proportional to Igh mRNA levels (Milcarek, Hartman et al. 1996).  
Weak poly(A) sites are used more efficiently in plasma cells than in B/ memory cells even in 
constructs in which there is no splicing between the sites. Polyadenylation therefore tips the 
balance towards secretory poly(A) site use in plasma cells (Milcarek and Hall 1985; Kobrin, 
Milcarek et al. 1986; Lassman, Matis et al. 1992; Lassman and Milcarek 1992; Matis, 
Martincic et al. 1996). Differences between plasma and memory B-cells are found in the 
polyadenylation machinery. These changes occur in the binding efficiency of basal factors 
Cleavage Stimulatory Factor CstF-64 and Cleavage Polyadenylation Specificity Factor CPSF-
100 (Edwalds-Gilbert and Milcarek 1995; Edwalds-Gilbert and Milcarek 1995). LPS 
induction of splenic B-cells increases CstF-64 and introduction of CstF-64 into chicken DT40 
B-cells results in Ig secretion (Takagaki, Seipelt et al. 1996), see Table 1. 
Both the Igh 5’ splice site in the last sec exon and the sec poly(A) sites are weak and in 
competition (Peterson and Perry 1989); overall splicing is decreased in plasma cells (Bruce, 
Dingle et al. 2003).  A shift in the SR-proteins is seen from the activating type (ASF/SF2) in 
B-cells to the repression type (SRp20) in plasma cells. The factors hnRNP F and U1A, both of 
which block the secretory-specific poly(A) site from functioning, are reduced in plasma cells 
(Veraldi, Arhin et al. 2001; Milcarek, Martincic et al. 2003; Alkan, Martincic et al. 2006)  and 
(Ma, Gunderson et al. 2006) which would allow the secretory site to function better. The 
major effectors in the alternative processing in B versus plasma cells are summarized in 
Table 1. 
The OCA-B transcription factor is up-regulated in plasma cells (Qin, Reichlin et al. 1998); it 
binds to oct2 at the Igh promoter. The CCNC complex of cyclin C and cdk8 along with PC4/ 
sub1 are induced by IRF4 in multiple myeloma a tumor of the plasma cells (Shaffer, Emre et 
al. 2008) and could act on the Igh gene to regulate transcription. 
We re-examined the micro-array data on gene expression in B versus plasma cells that we 
published previously (Martincic, Alkan et al. 2009) to concentrate on transcription 
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elongation factors. The data are shown Table 1. The robust up-regulation of blimp-1 and 
IRF4 are presented as controls to show that the plasma cells are at the fully differentiated 
stage, as expected. The ELL2 and PC4 mRNA are the next most highly induced in plasma 
cells, increased approximately 6-fold over B cells. Most of the other factors like cdk8, cyclin 
C and eaf2 are moderately induced in our test plasma cells (<2-fold). But it is of interest that 
supt5h (a DSIF subunit) and pTEFb subunits cdk9 and cyclin T are also induced ~2-fold as is 
the relA subunit of NF-kB, a transcription factor that binds to the Igh enhancer region.  
 
Factors, function 
5’ splice favored 
(B and memory 
cells) 
Sec poly(A) site favored 
(Plasma cells/ myeloma) 
Igh mRNA form Mb> sec Sec>>mb 
Igh mRNA abundance 1 20-100 greater 
OCA-B, Igh promoter binding Low Higher 
Blimp-1, IRF4, general transcription 
factors 
Low 6-300 X 
relA, NF-kB transcription factor Low ~2X 
Cdk8, cyclin C. PC4, CTD 
phosphorylation 
Low ~4X in myeloma 
RNA polymerase loading on Igh Low High 
Ser-2, ser-5 P on CTD RNAP-II  Igh 
promoter 
Low ~8X 
LPS induced CstF-64, polyadenyation - ~6X 
ELL2, transcription elongation Low ~6X 
pTEFb, Supt5h, elongation Low ~2X 
hnRNP F, polyadenylation inhibitor ~4X Low 
U1A, polyadenylation inhibitor ~4X Low 
ASF/SF, splicing High Low 
SRp20, splicing Low High 
Pausing at sec poly(A) site yes same 
Table 1. Expression levels in B versus plasma cells, see text for references 
Taking all this information into account, it is clear that the plasma cell program for 
expression of the secreted form of the Igh mRNA is indeed complex. Transcription and 
elongation are a unifying theme for many of the changes seen. There is up-regulation of a 
number of transcription factors including the NF-kB subunit relA. There are changes to the 
phosphorylation of the CTD of RNAP-II and the enzymes that do this. Transcription 
elongation factors like ELL2 are up-regulated. Each of these aspects of gene expression will 
be discussed in turn, below. 
3.1 Do factors bound at the Igh promoter or enhancer influence alternative Igh RNA 
processing? 
The original studies of the Igh gene showed only a small enhancement of transcription 
activity in plasma cells over that seen in B-cells (Kelly and Perry 1986). Those studies used 
the incorporation of radioactive nucleotides and filter hybridization. Our studies using 
chromatin immunoprecipitation showed only a 2-fold change in the amount of RNA 
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polymerase II on the Igh TATA region (see Figure 2). Meanwhile, the modifications of 
polymerases differ between the cell types and may contribute significantly to processing 
changes; this will be discussed in a subsequent section.  But the alternative processing of the 
Igh gene appears to obey the same rules with respect to alternative processing whether the 
gene is intact (Kobrin, Milcarek et al. 1986) or if the CH1 exon to the 3’ end are placed as a 
cassette linked to an SV40 promoter (Peterson and Perry 1986). Therefore most studies have 
ignored the contribution of the Igh promoter to regulation. However, recent studies linking 
elongation and pausing to alternative processing of RNA implicate the promoter; the 
changes we saw in polymerase modifications also suggest a re-examination of factors that 
might act the Igh promoter. 
Neither blimp-1 nor IRF-4 has any mapped interactions with the Igh promoter. But TAF105 
is a lymphocyte specific “general transcription factor” found in a small fraction of TFIID 
complexes (Dikstein, Zhou et al. 1996; Wolstein, Silkov et al. 2000). TAF105 is dispensable 
for B-cell differentiation (Freiman, Albright et al. 2002); its role in immunoglobulin heavy 
chain (Igh) expression is unknown. Meanwhile, OCA-B (OBF-1/Bob1) is a transcription 
factor that binds indirectly to the octamer sequence in the Igh promoter through oct2, 
interacts with TAF105 (Wolstein, Silkov et al. 2000) and is up-regulated in plasma cells (Qin, 
Reichlin et al. 1998). OCA-B deficient mice show strain-specific, partial blocks at multiple 
stages of B-cell maturation and a complete disruption of germinal center formation in all 
strains. IgM secretion (an early event) may be normal while IgG+ cell expansion (a later 
event) is disrupted but not isotype switching (Teitell 2003). Gene array studies show that 
OCA-B may act on genes for cell expansion, like cyclin D3 (Kim, Siegel et al. 2003), not Igh 
secretion per se, although its role in alternative processing has not been extensively studied. 
Oct2 was originally believed to work on Igh expression but studies with knock-out mice 
reveal that its major role is on regulation of the IL-5 receptor (Emslie, D'Costa et al. 2008). 
But these factors may direct RNAP-II modifications. 
The subunits cdk8 and cyclin C (CCNC) are involved in modification of the RNA 
polymerase and might possibly thus serve a regulatory role in alternative Igh mRNA 
processing. These two are up-regulated in the condition known as multiple myeloma 
(Shaffer, Emre et al. 2008) a tumor of a plasma cell, along with PC4 (aka sub1 in yeast). Both 
cdk8 and cyclin C have been shown to be associated with the mediator complex. Mediator is 
a co-activator of transcription; the composition of this large complex may vary with the 
promoter in response to different DNA-bound activators, acting as a link between them and 
the transcription start-site (Sato, Tomomori-Sato et al. 2004). The order of addition of 
mediator vs RNAP-II may vary for different genes (Lewis and Reinberg 2003). 
Transcriptional enhancers like p53 and VP16 target different mediator subunits (Taatjes, 
Marr et al. 2004) and other general transcription factors like TFIIB and TFIIA ; meanwhile 
herpes virus 1 ICP4 targets TFIID, another general transcription factor bound at the 
promoter (Grondin and DeLuca 2000). CPSF, a subunit of the polyadenylation complex, was 
found associated with TFIID at the promoter and subsequently transferred to the elongating 
polymerase (Dantonel, Murthy et al. 1997). Transcriptional activators like GAL4-VP16 
enhance the polyadenylation of mRNA precursors  through interaction with elongation 
factors (Nagaike, Logan et al. 2011). It will be interesting to determine if CCNC functions in 
alternative Igh RNA processing. The role of CTD phosphorylation is discussed below. 
The nuclear factor kappa B (NF-kB) was first discovered in B-cells but subsequently found in 
most other cells. It has been shown to regulate a number of important processes including the 
cell cycle (Hinz, Krappmann et al. 1999). The relA and p50 subunits are released from an 
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inhibitor and allowed to enter the nucleus on activation of NF-kB; expression is constitutive in 
mature B-cells (Fields, Seufzer et al. 2000). There are binding sites for NF-kB throughout the 
Igh gene (Horowitz, Zalazowski et al. 1999). We see an increase in relA in plasma cells. What 
role NF-kB plays in the differential expression of the Igh mRNAs is not known but may 
provide insights into the role of activation of promoters and increased polyadenylation.  
The nuclear transcription factor C/EBP , also called NF-IL6, regulates a variety of genes 
involved in diverse functions such as acute phase response,(Poli 1998) immune 
function,(Screpanti, Romani et al. 1995; Tanaka, Akira et al. 1995; Poli 1998) 
inflammation,(Lekstrom-Himes and Xanthopoulos 1999) and hematopoiesis  (Calkhoven, 
Muller et al. 2000). Binding sites for factor C/EBP are found in the Igh enhancer and a 
variety of genes important in lymphocytes and multiple myeloma (Pal, Janz et al. 2009). 
Deletion of the C/EBP gene in mice results in impaired generation of B lymphocytes 
(Chen, Liu et al. 1997). Therefore it is a candidate for up-regulating Igh transcription leading 
ultimately to Ig secretion. 
The composition of transcription complexes assembled on different core promoters has been 
shown to affect splice site selection during pre-mRNA splicing (Cramer, Caceres et al. 1999; 
Zhao, Hyman et al. 1999). The promoter sequence motif in the Simian Virus 40 (SV40) early 
core promoter influences alternative splicing presumably by influencing both the 
composition of the transcription complex that assembles and the processivity of 
transcription elongation (Gendra, Colgan et al. 2007). Thus the common theme between the 
Igh and SV40 promoters, both of which were used to drive first poly(A) site use in the Igh 
locus, is that they are strong promoters in plasma cells. The Igh gene may get that way by 
the up-regulation of trans acting factors like cdk8 and cyclin C or something else while the 
SV40 promoter is inherently strong and something may be lacking or inhibitory in B cells 
which does not allow it to function optimally.  There is still much to learn about this. 
The presence or absence of the TATA element in the core promoter can change the way the 
NF-kB gene itself engages elongation and pausing factors (Amir-Zilberstein, Ainbinder et al. 
2007). Thus there is a tight link between the promoter, initiation, elongation and 
polyadenylation in NF-kB. Interestingly, different Igh V regions vary with respect to the 
presence or absence of the TATA box (Johnston, Wood et al. 2006) so this linkage of TATA 
to elongation seen  in NF-kB may not be applicable to the Igh family. 
3.2 RNA polymerase II phosphorylation is altered on the Igh gene in plasma cells 
Productive metazoan gene expression involves recruitment of RNAP-II to the promoter 
region, subsequent initiation of transcription, followed by, in many cases, a pause which is 
then released to allow elongation and RNA processing. The resulting mature mRNA is 
spliced and polyadenylated as a part of the transcription elongation “machine”. At least 50 
proteins are involved in DNA recognition and assembly of a transcription complex on a 
promoter. RNAP-II, general transcription factors, gene-specific DNA binding proteins, the 
mediator complexes and nucleosome-modifying factors are involved. Modifications occur in 
the chromatin, the RNA polymerase II itself, elongation and processing factors; this is a 
concerted, multifaceted transformation, reviewed in (Selth, Sigurdsson et al. 2010) and 
(Hargreaves, Horng et al. 2009). Many excellent reviews have been published that deal with 
the transition from initiation to elongation, for example (Nechaev and Adelman 2011) and 
the linkage of elongation to RNA processing, DNA repair, Ig gene hypermutation, nuclear 
www.intechopen.com
 
RNA Processing 
 
34
export and sister chromatid cohesion (Akhtar, Heidemann et al. 2009; Perales and Bentley 
2009).  
The RNA polymerase large subunit contains a carboxyl-terminal domain (CTD) which can 
be phosphorylated in multiple positions of the 52 repeats of the heptad consensus: Tyrosine-
Serine-Proline-Threonine-Serine-Proline-Serine, reviewed in (Muñoz, de la Mata et al. 2010). 
Phosphorylations of Ser-2, ser-5 and ser-7 of the CTD are the major modifications but cis-
trans isomerization (Xu and Manley 2007) as well as serine and threonine glycosylation can 
occur. The multilayered phosphorylation of the CTD is brought about by a series of 
enzymatic activities during initiation and elongation. Near the promoter, TFIIH 
(Kin28/cdk7) phosphorylates ser-5 and ser-7 of the heptad consensus (Akhtar, Heidemann 
et al. 2009; Glover-Cutter, Larochelle et al. 2009). Associated with mediator complex are 
cyclin C and cdk8 which also phosphorylate primarily ser-5 although some activity on ser-2 
has been noted. In a plasma cell tumor cdk8, cyclin C and PC4 the mammailian homolog of 
the yeast sub1 are up-regulated (Shaffer, Emre et al. 2008); this is highly suggestive of a role 
for them in Igh mRNA production. Yeast sub1 has been shown to interact with all the CTD 
kinases and it may have multiple actions throughout the transcription cycle (Garcia, 
Rosonina et al. 2010). Surprisingly, our experiments did not show a role for PC4/ sub1 in 
directing alternative Igh mRNA expression (Martincic, Alkan et al. 2009) and below.  
The primary phosphorylation of ser-2 occurs through the action of positive transcription 
elongation factor b, aka pTEFb (composed of Cyclin T1 or 2 & cdk9). The pivotal role of 
pTEFb in elongation has been described in numerous studies, reviewed in (Pirngruber, 
Schhebet et al. 2009), and discussed below. Whole genome studies of CTD phosphorylation 
in S. cerevisiae reveal a complex pattern of the three ser-phosphorylations that are gene 
specific with the ser-7 marks being dynamic, i.e. placed anew most likely by bur1, the yeast 
cyclin dependent kinase (Tietjen, Zhang et al. 2010). Thus the myriad combinations of these 
three modifications on 52 repeats, alone or together, allows for tremendous multiplicity in 
the association of factors with the CTD.  
These phosphorylations of the CTD allow for the associations of histone modifying enzymes 
primarily to histone H3; activating modifications include acetylation at K9 and K14 and 
methylations at K4, K36 and K79 to link the CTD to processing factors and possibly help 
unwind the DNA from the histone core.  
 
Kinases 
TFIIH 
Yeast 
Kin28/cdk7 
Cyclin C/cdk8 
aka CCNC 
Cyclin T/cdk9 
aka pTEFb 
? 
RNAP-II CTD 
phosphorylation 
Ser-5, ser-7 Ser-5> ser-2 Ser-2>>ser-5 ? 
Co-factor? …........................Sub1/PC4 ??……………………………… 
Interactions/enzymes
MLL, SMYD2 
yeast set1, 
set7/9 
NSD1 
Yeast set2 
Dot1L 
Activating Histone 
H3 methylations 
Lysine 4 Lysine 36 Lysine 79 
Table 2. Linkage between the activation of RNA polymerase II and histone H3 
modifications. 
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With this in mind,  we  investigated the patterns of polymerase loading and serine 
phosphorylation of CTD on the Igh gene in two cell lines representing either B-cells or 
plasma cells, which are noteworthy in that they carry the identical IgG2a heavy chain gene 
(Shell, Martincic et al. 2007). Using chromatin immunoprecipitation and real time PCR 
across the Igh locus (probes illustrated in Figure 2) we found that there is a large increase in 
both ser-5 and ser-2 phosphorylation of CTD near the 5’ end in plasma cells concomitant 
with high Ig heavy chain secretory-specific mRNA production. Factors for polyadenylation 
(CPSF-160, CstF-50 and -64), transcription elongation (ELL2), and co-transcription activation 
(PC4) can be found in much greater abundance near the 5’ start site in the plasma cells than 
in B-cells, See Figure 3 for summary of those data. We concluded that increased 
phosphorylation of RNA polymerase II at the start of transcription and the increased 
association of polyadenylation, and elongation/ co-transcription factors are important in 
influencing alternative mRNA processing of the Ig heavy chain gene. Using siRNA to ELL2 
reduced the binding of ELL2 and CstF-64 to the Igh TATA region (Figure 3) implying a 
sequential relationship among those factors. 
The drug D-ribo-furanosyl-benzimidazole (DRB) can be used to inhibit the action of pTEFb 
on its targets  (Yamaguchi, Wada et al. 1998). We showed that treatment of plasma cells with 
DRB inhibits ser-2 phosphorylation and causes the unmodified RNAP-II on the Ig heavy 
chain in plasma cells to stall near the 5’-end of the Ig gene (Shell, Martincic et al. 2007) and 
Figure 3. DRB also causes the decreased association of ELL2, PC4 and the polyadenylation 
factor CstF-64, suggesting that their binding to RNAP-II require the ser-5 and ser-2 
 
 
Fig. 3. Co-activators are differentially loaded onto the IgG2a heavy chain near the 
promoter. Chromatin was immune- precipitated with antibodies against the indicated 
factors. The resulting DNA was amplified in a QPCR with primers for the 5’ end of the Ig 
gamma 2a H chain transcript, as designated TATA on map of Igh, Figure 2. Grey boxes are 
the signals from A20 B-cells and white boxes the plasma cell AxJ.  Data are simplified and 
compiled here from two papers: (Shell, Martincic et al. 2007), normal and DRB treatment  
and siell2 data  (Martincic, Alkan et al. 2009). The error bars and statistics showing 
significance are detailed in those publications and omitted here for clarity. 
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modifications. The increased CTD phosphorylation, polyadenylation factor, and elongation 
factor association at the 5’ end in plasma cells vs B-cells are consistent with an RNAP-II on 
the Ig heavy chain gene in plasma cells that is primed for recognition of the proximal 
(secretory-specific) poly(A) site. Such polymerases would be expected to produce mRNA, 
leading to high abundance. The nascent RNAs could be efficiently processed, most likely at 
the promoter proximal poly(A) site, thereby producing the secreted form of the Igh mRNA 
and the protein. 
In contrast to plasma cells, in the B-cells the polymerase on the Ig heavy chain gene is much 
less heavily modified with either type of ser-phosphorylation, polyadenylation factors, ELL2 
or PC4. These polymerases in B-cells seem more likely to allow the weak donor site for the 
alternative CH3 to M1 splice to be set up and are not as competent for polyadenylation at 
the weak sec poly(A) site. Of course the presence of inhibitory factors also plays a role (see 
below). It appears that the polymerase in B-cells lacking the ser-2 and ser-5 modifications 
never acquire them in bulk even downstream (Shell, Martincic et al. 2007). Thus they may be 
dubbed “pauci-polymerases” in so far as they lack the modifications and the factors 
necessary to efficiently polyadenylate  the RNA.  This also results in decreased mRNA yield 
per polymerase pass. This is consistent with recent observations that a strong promoter 
directs strong association of polyadenylation factors with the polymerase (Nagaike, Logan 
et al. 2011). 
The co-transcriptional processing of nascent RNA can be an inefficient activity even when 
RNAP-II is transiting the gene. This is evident in the c-H-ras gene where a mutation making 
a splice stronger significantly up-regulates mature mRNA production and leads to 
oncogenesis without changing transcription rate (Cohen and Leninson 1988). In the 
prothrombin gene, increased efficiency of the mRNA 3’ end formation and thus protein 
production is brought about by mutation near the poly(A) site with no change in 
transcription rate. The mutation at the poly(A) site causes increased risk for blood clots in 
people carrying the mutation (Gehring, Frede et al. 2001). So weak cis acting signals allow 
the polymerase to avoid co-transcription processing; this along with pauci-polymerases can 
also result in low production of mature mRNA. 
Changes in the level of rate-limiting, trans acting factors, like CstF-64 following 
lipopolysaccharide stimulation in B-cells (Takagaki, Seipelt et al. 1996) or macrophages 
(Shell, Hesse et al. 2005) or in the cell cycle (Martincic, Campbell et al. 1998), can also 
increase mRNA polyadenylation (Getz, Elder et al. 1976). Changes in the level of ELL2, a 
transcription elongation factor, increase use of the first poly(A) site in the Igh gene 
(Martincic, Alkan et al. 2009), an important step for plasma cell development. Therefore, the 
throughput of initiated transcripts to polyadenylated, mature mRNA is limited by a.) cis 
acting elements in the nascent RNA, b.) the availability of trans acting polyadenylation 
factors and c.) the elongation factors and their requisite associations with the polymerase at 
pause sites.  
3.3 Do modifications of the histones regulate alternative processing of Igh RNA? 
The appearance of mono-, di-, and tri-methylated forms of histone H3, modified at Lysine 4, 
Lysine 36 or Lysine 79 (aka H3K4me2/3 , H3K36me3 and  H3K79me1,2,3 ) are signals of gene 
activation (Steger, Lefterova et al. 2008). The K4 mark is associated with the multiple lineage 
leukemia gene MLL in mammalian cells and yeast SET1 and COMPASS at a number of gene 
loci (Wang, Lin et al. 2009). MLL interacts with Menin to form a histone methyltransferase 
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for H3K4 (Yokoyama, Lin et al. 2004) which results in the expression of the developmentally 
important Hoxa7 and -9 genes, hallmarks of MLL induced leukemia (Ayton and Cleary 
2003).  
The ser-5 modification of the CTD of RNAP-II directs histone modifications especially at  
H3K4, see Table 2. The H3K36me3 mark has been associated with recruitment of splicing 
factors to exons (Spies, Nielsen et al. 2009) and it can modulate alternative splicing by 
recruiting Polypyrimidine Tract Binding (PTB) protein to sub-optimal exons (Luco, Pan et al. 
2010). The yeast SET2 enzyme binds to a peptide of CTD phosphorylated at ser-2 and ser-5 
with two heptapeptide repeats and three flanking NH2-terminal residues, whereas a single 
CTD repeat is insufficient for binding (Vojnic, Simon et al. 2006). The mammalian homolog 
of SET2 is NSD1 which has been shown to link H3K36methylation and leukemogenesis 
(Wang, Cai et al. 2007). H3K79 methylations are brought about by Dot1L (Steger, Lefterova 
et al. 2008); the linkage of Dot1L action to CTD modifications has thus far not been made. 
Conversion of H3K79 monomethylation into di- and tri-methylation is correlated with the 
transition from low- to high-level gene transcription. The multi-subunit Dot1 complex 
(DotCom) includes MLL partners: ENL, AF9/MLLT3, AF17/MLLT6, and AF10/MLLT10 
(Mohan, Herz et al. 2010). In another study ENL was shown to associate with Dot1L to 
methylate K79 (Mueller, Bach et al. 2007); ENL may thus link the super elongation complex 
(SEC) with H3K79 modifications, see Table 2.  
We saw no changes in H3 K9 or K14 acetylation on the Igh by chromatin IP in previous 
studies although unusual high acetylation was seen near the Igh enhancer region, consistent 
with its role in gene activation (Shell, Martincic et al. 2007). However, terminal B cell 
differentiation in vitro was induced by the inhibition of histone acetylases (Lee, Bottaro et al. 
2003) and knocking out histone deactylase-2  in chicken B cells had an influence on both 
transcription and alternative processing (Takami, Kikuchi et al. 1999). Studies of other 
modifications of the histones are clearly warranted and on-going in the Igh locus to 
understand how these might control alternative processing. 
3.4 Polyadenylation of Igh RNA is altered in plasma cells 
Most mature eukaryotic mRNAs contain a homopolymer (20-250 nts) of adenosines, the 3’ 
poly(A) tail, which controls mRNA degradation, mRNA export, and translation efficiency in 
somatic cells (Sachs and Wahle 1993) and in oocyte maturation (Sheets, Wu et al. 1995). 
When poly(A) tails were first discovered, hybridization studies revealed some exceptions to 
the rule, there are unique poly(A) minus mRNAs (Milcarek, Price et al. 1974). A recent look 
at mRNA expression by deep sequencing has revealed both poly(A)-plus and minus 
mRNAs but these poly(A)-minus mRNAs are in the minority (Yang, Duff et al. 2011).  
Despite these exceptions, polyadenylation is a common means for 3’ end formation; many 
genes have more than one poly(A) site (Lutz and Moreira 2011). The sequence requirements 
for poly(A) tail addition are an AAUAAA or a closely related poly(A) signal, followed by 
the site where cleavage and poly(A) addition will occur and from 30-50 nts downstream, a 
GU or U rich downstream sequence, illustrated in Figure 4. Minimal protein factors 
required for the coupled pre-mRNA cleavage and polyadenylation include: cleavage 
stimulatory factor trimer (CstF 77, 64 & 50); poly(A) polymerase (PAP); cleavage factors (CF) 
Im and IIm.; nuclear and cleavage and polyadenylation specificity factor complex (CPSF 160, 
100, 73 & 30 kDa). CPSF recognizes the AAUAAA signal and CstF recognizes the 
downstream element. Nuclear poly(A) binding proteins II, involved in transport and 
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cytoplasmic stability, are bound to the newly formed poly(A) tail. CPSF-73 is the 
presumptive endonuclease for cleavage of the pre-mRNA (Mandel, Kaneko et al. 2006). 
These factors interact to form a large complex in vitro (Moore, Skolnik-David et al. 1988; 
Stefano and Adams 1988) (Veraldi, Edwalds-Gilbert et al. 2000) and in vivo (Shi, Di 
Giammartino et al. 2009). CPSF interacts with TFIID (transcription factor II D) then RNA 
polymerase II at the promoter and remains associated with RNAP-II in HeLa cells 
(Dantonel, Murthy et al. 1997; McCracken, Fong et al. 1997) and on the Igh gene as we have 
shown (Shell, Martincic et al. 2007) 
 
 
Fig. 4. Minimal factors required for poly(A) tail addition at 3’ end of RNA. 
The CstF trimer is required for the cleavage reaction (MacDonald, Wilusz et al. 1994), 
interacts with CPSF via its 77 kDa subunit, and binds the GU-rich region downstream of the 
poly(A) site via its 64 kDa subunit (Wilusz and Shenk 1990; Takagaki, MacDonald et al. 
1992; Takagaki and Manley 1997). The 50 kDa subunit  interacts with BRCA1/BARD1 to 
modulate polyadenylation during DNA repair (Kleiman and Manley 2001), and with 
RNAP-II through CTD (McCracken, Fong et al. 1997). The 77 kDa subunit of CstF contains 
the putative nuclear localization signal for transporting the 50:77:64 trimer into the nucleus 
(Takagaki and Manley 1994). 
3.5 Alterations in trans-acting factors for polyadenylation in B and plasma cells 
Nascent RNA cleavage in polyadenylation can be blocked by U1A (Phillips, Pachikara et al. 
2004; Ma, Gunderson et al. 2006) or hnRNP F (Veraldi, Arhin et al. 2001); the levels of both 
of these are high in B-cells and lower in plasma cells (summarized in Table 1) and (Ma, 
Gunderson et al. 2006) consistent with a loss of their inhibitory function on the poly(A) sites 
in plasma cells. While hnRNP F might be expected to block any poly(A) site based on its 
sequence preference for downstream regions (Alkan, Martincic et al. 2006), we found by a 
micro-array analyses of hnRNP F transfected cells that only some genes were affected, most 
notable among these were secretory Igh and  ELL2, a transcription elongation factor 
(Martincic, Alkan et al. 2009). The finding that there are U1A binding sites up-stream of the 
Igh mu secretory poly(A) site indicates a selectivity consistent with the observed increased 
use of the site when U1A levels fall (Phillips and Virtanen 1997). The data clearly show that 
a change in the levels of these factors influences the polyadenylation of the Igh secretory 
site. The smaller number of polyadenylation factors associated with the B cell RNAP-II may 
not recognize the AAUAAA and downstream regions of the secretory poly(A) site because 
these two RNPs block access. 
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Recently, using a knock-down and whole genome array approach, the U1 snRNA itself, not 
the U1A protein, was shown to protect pre-mRNA from premature cleavage and 
polyadenylation (Kaida, Berg et al. 2010). This reveals a function for U1 RNA independent 
of splicing where its interaction with the splice site in the nascent RNA  plays a seminal role. 
In another recent study a fraction of the U1 snRNA, without any of the normal RNP 
proteins, was found associated with TAF15 aka TAFII-68  (Jobert, Pinzon et al. 2009). This 
TAF interacts with a distinct population of TFIID so U1 snRNA may play a heretofore 
unrecognized role in transcription initiation. These unique aspects of U1 snRNA function 
have not been investigated in B or plasma cells. 
The CstF-64 gene (CSTF2) maps to the X chromosome; expression of the protein fluctuates 
and is rate-limiting for the CstF complex formation (Martincic, Campbell et al. 1998). 
Knocking out CstF2 in chicken B-cells resulted in changes to viability, Igh transcription,  and 
alternative splicing  (Takagaki and Manley 1998). An alternative form of CstF-64 (CSTF2T) 
was found originally in testes, but then it was  also found to be expressed in other tissues 
including B-cells and plasma cells. The CSTF2T gene maps to an autosome allowing for its 
transcription in spermatogenesis when the X chromosome is suppressed (Dass, McMahon et 
al. 2001).  CSTF2T protein is induced by LPS in splenocytes just like CSTF2. Deletion of the 
CSTF2T gene gives rise to spermatogenetic defects but no immunological defects were 
associated with its loss (Hockert, Martincic et al. 2011). Thus CSTF2T does not play an 
indispensible part in Igh expression. 
3.6 Splicing of Igh RNA is altered in plasma cells 
RNA splicing occurs through a concerted series of events facilitated by the U family of small 
Ribonuclear protein particles (snRNPs) 1, 2, 4, 5, 6 and their associated proteins. Serine 
arginine (SR) proteins, e.g. SF2/ASF, SRp20, often act as enhancers for splicing while in 
general heterogenous nuclear ribonucleoproteins (hnRNPs) act as spoilers. The balance 
between these has been shown to control many genes, reviewed in (House and Lynch 2008). 
Changes in the levels of the splicing factors in various B cell types (Bruce, Dingle et al. 2003) 
and during development have been shown to alter splicing patterns (Expert-Bezancon, 
Sureau et al. 2004). For, example, SRp20 plays an important role in alternative splicing of the 
ED1 exon (de la Mata and Kornblihtt 2006). The finding that the levels of SRp20 increase in 
plasma cells is intriguing (Table 1). How SRp20 is influencing the balance between splicing 
and polyadenylation is not known. It is tempting to speculate that it blocks use of the weak 
splice site in the secretory exon in plasma cells. 
RNA processing events and transcription are tightly linked (Proudfoot, Furger et al. 2002). 
The recruitment of different factors to control splice site selection occurs on the carboxyl-
terminal domain (CTD) of RNAP-II (McCracken, Fong et al. 1997). Elongation rates were 
shown to modulate alternative splicing with high processivity of the polymerase correlating 
with exon skipping, reviewed in (Kornblihtt 2006). A key role for pTEFb was found for 
coupling transcription elongation with alternative splicing (Barboric, Lenasi et al. 2009). But 
chromatin modifications also seem to be important. For example, H3K36me3 marks are 
associated with recruitment of splicing factors to exons (Spies, Nielsen et al. 2009). The 
histone tail–binding protein MORF-related gene 15 (MRG15), a component of the 
retinoblastoma binding protein 2 (RBP2)/H3-K4 demethylase complex, recruits 
Polypyrimidine Tract Binding protein to sub-optimal exons (Luco, Pan et al. 2010). The 
mammalian ortholog of the SWI/SNF (SWItch/Sucrose NonFermentable) yeast nucleosome 
remodeling complex has been shown to play a role in CD44 alternative splicing (Batsche, 
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Yaniv et al. 2006). In addition, H3K9 hyperacetylation outside the promoter stimulates 
alternative splicing (Schor, Rascovan et al. 2009).  
Several models for coupling alternative splicing to elongation or chromatin have been 
considered recently. The modulation of elongation rates to splicing has been advocated (de 
la Mata, Lafaille et al. 2010). Meanwhile nucleosome positioning has been discussed as a 
regulator (Tilgner, Nikolaou et al. 2009). And chromatin as a scaffold for pre-mRNA splicing 
regulation has been discussed (Allemand, Batsché et al. 2008). While there is a link between 
transcription elongation and RNA splicing, the details of these connections are still 
emerging and chromatin modifications may play a large role as well. Our data clearly 
indicate a role for transcription elongation factor ELL2 in modulating alternative splicing 
(see below) but much more needs to be done to understand how this is accomplished. 
4. RNAP-II elongation is altered in Igh gene regulated RNA processing 
4.1 Elongation regulation is crucial 
Photo-bleaching of fluorescent RNA polymerase II in living cells reveals that transcription 
elongation is much faster than expected but the polymerases enters a paused state for 
unexpectedly long times (Darzacq, Sahav-Tal et al. 2007). Genome wide studies indicated 
that a number of developmentally important genes in Drosophila embryos that were not yet 
being actively transcribed but are scheduled to be expressed in subsequent stages have a 
paused polymerase at the 5’ end (Zeitlinger, Stark et al. 2007).  
The dysregulation of elongation and subsequent aberrant gene expression have been 
strongly associated with the genesis of several cancers. The von Hippel-Lindau tumor 
suppressor gene (VHL) predisposes individuals to a variety of tumors by inhibiting elongin 
SIII, a normal component of the elongation machinery (Duan, Pause et al. 1995). The tumor 
suppressor Cdc73, a component of the mPAF elongation complex, is inactivated by 
mutation in hereditary and sporadic parathyroid tumors and alters poly(A) site choice 
(Rozenblatt-Rosen, Nagaike et al. 2009).  
In multiple lineage leukemia (MLL), which has provided an important window to the role of 
elongation and chromatin modification (Shilatifard 1998) and (Lin, Smith et al. 2010; Mohan, 
Herz et al. 2010), fusions occur with different elongation factors in different tumors to bring 
MLL protein in close association with the start of target genes, like the hox genes, and 
thereby inappropriately activate them (Meyer, Kowarz et al. 2009). The regulation of 
pausing and elongation are therefore emerging as important steps in gene regulation.  
4.2 ELL genes in general transcription elongation 
ELL1 (Eleven-nineteen Lysine-rich Leukemia gene 1) was discovered as a translocation 
partner with the MLL gene in individuals with acute leukemia (Thirman, Levitan et al. 
1994). The closely related family member ELL2, isolated by homology with ELL1, can also 
stimulate RNAP-II elongation in vitro (Shilatifard, Lane et al. 1996), (Shilatifard, Duan et al. 
1997), and (Miller, Williams et al. 2000). ELL3 is primarily expressed in testis and tumor 
cells; it also increases the catalytic rate of transcription elongation in vitro (Miller, Williams 
et al. 2000). 
The mRNAs for the ELL1 and 2 are widely expressed but vary from tissue to tissue, 
suggesting they may serve a regulatory role (Shilatifard, Duan et al. 1997). Human ELL1 
protein is 621 amino-acids long while ELL2 is 640, see Figure 5 for ELL2. They are very 
similar from aa 1-345. This region is responsible for elongation enhancement. The segments 
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of ELL2 from aa 168-180 and from 239 to 250 were shown to interact with mediator in a 
proteomic screen which has not yet been verified by functional assays (Sato, Tomomori-Sato 
et al. 2004). ELL1 and 2 differ from aa ~352-443 and 473-516, amino acids that map primarily 
to the later ~75% of exon 8. The 352-516 region differences may explain some of the unique 
associations of ELL1 versus ELL2. This region is rich in hydrophobic amino acids like 
proline and leucine but also contains hydrophilic charged residues like lysine and 
glutamate. No known protein motif has been identified in this domain. The mid-portion of 
ELL has been determined to be the region that is required for its association with heat shock 
puffs in Drosophila (Gerber, Shilatifard et al. 2005).  
From aa 520 to the carboxyl-end ELL1 and 2 are very similar. The C-terminal domain is 
conserved in all the members of the ELL-family including Drosophila; it shares homology 
with occludin, an integral plasma membrane protein located in tight junctions. The 
functional significance of the homology is unknown but this C-terminal domain is required 
for viability in Drosophila (Eissenberg, Ma et al. 2002; Gerber, Shilatifard et al. 2005). The C-
terminal domain of ELL is sufficient for immortalization of myeloid progenitors most likely 
through its interactions with p53, although the MLL:ELL fusion is more efficient than ELL 
alone (Wiederschain, Kawai et al. 2003).  
 
 100 200 300 400 500 600 640 
NH2        COOH  
   133,8, 186     In-frame methionine 
        Occuldin-like & p53 
      Elongation activity 
        Differs from ELL1 
            Mediator interactions 
           EAF1 interactions 
            
           EAF2 interaction 
         
Fig. 5. Map of ELL2 indicating important regions discussed in text.  
In addition, ELL1 was found to bind to the promoter and to have direct transcriptional 
activity on the thrombospodin-1 gene in mammalian cells (Zhou, Feng et al. 2009). The DNA 
binding domain maps to the aa 1-45. Studies using zebrafish, confirmed that ELL regulates 
TSP-1 mRNA expression in vivo; the conserved C-domain found in MLL fusions was the 
region involved in this activation (Zhou, Feng et al. 2009). This is the first report of ELL 
acting without binding to RNAP-II. 
4.3 EAF genes in transcription elongation 
EAF1 and EAF2 (ELL associated factors 1 and 2) were discovered via two-hybrid and co-IP 
studies to be associated with ELL. The association of EAF1 was mapped to amino acids 28-
117 and 508-621 of ELL1 while the EAF2 associations mapped to aa 23 to 90 of ELL1 (Luo, 
Lavau et al. 2001; Simone, Luo et al. 2003), see Figure 5. Both EAF1 and 2 are required for 
viability in Drosophila (Liu, Hu et al. 2009). EAF2/U19/FESTA is associated with another 
elongation factor, SII/TCEA/TFIIS. The eaf2-/- mice are viable but form tumors in the 
spleen and prostate later in life (Xiao, Zhang et al. 2008). Therefore, not having EAF2 is  not 
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fatal but sufficient to produce a back-up at the mature B-cell stage. Investigation of the 
production of secreted Igh in the eaf2-/- mice would be an important problem. 
4.4 pTEFb in transcription elongation 
Cyclin T1 or T2 and cdk9, a cyclin dependent kinase, form the core of pTEFb, which has been 
implicated in many studies of gene regulation through alleviation of RNAP-II pausing (He, 
Pezda et al. 2006). The c-myc gene was among the earliest genes studied that displays a strong 
pause site, which can either be alleviated or cause transcription termination leading to aborted 
mRNA production (Roberts and Bentley 1992). Recent studies have shown that myc requires 
pTEFb, the positive transcription elongation factor, to relieve the pause and empower the 
polymerase to make mature mRNA, or in other words, increase thoughput (Rahl, Lin et al. 
2010). The heat shock genes were recognized as having a paused polymerase with a 
requirement for pTEFb to drive elongation (Lis, Mason et al. 2000). The factor pTEFb has been 
shown to be required for the expression or repression of several immunologically important 
genes including AIRE (Oven, Brdickova et al. 2007), p53 (Gomes, Bjerke et al. 2006), runx in 
double positive T cells (Jiang and Peterlin 2008) and primary response genes in macrophages 
following Toll-Like-Receptor signaling (Hargreaves, Horng et al. 2009). Thus an examination 
of the pTEFb factor is important for understanding pausing and subsequent elongation. 
Inactive pTEFb is associated with the small nuclear 7SK snRNA and HEXIM 1 or 2 plus 
other proteins. HEXIM is induced by a hexamethylene bis-acetamide and has no introns. Its 
levels vary with developmental stage in a number of studies. HEXIM molecules can 
associate as homo- or hetero-dimers, through their carboxyl-terminal tails (Dulac, Michels et 
al. 2005). Multiple complexes of HEXIM dimers with their associated pTEFb bind to 7SK 
with a conformation change in 7SK structure (Krueger, Varzavand et al. 2010); cdk9 is thus 
inhibited in its enzymatic ability to phosphorylate substrates. The inactive form of pTEFb is 
released from HEXIM and binds other factors to become activated. The equilibrium between 
active and inactive forms shifts based on the amount of HEXIM expressed,  linking the 
pTEFb equilibrium to the intracellular transcriptional demands, proliferation, and 
differentiated states of cells (He, Pezda et al. 2006). When pTEFb is released from the 
inactive state it can be brought to the DNA: RNA polymerase complex by Brd4 through 
recognition of acetylated chromatin structures (Vollmuth, Blankenfeldt et al. 2009) or to 
virus transcription by specialized mechanisms.  
The DRB sensitive factor DSIF (composed of Spt1 and Spt5(h) aka p160) and a multi-subunit 
negative elongation factor (NELF) act together to arrest RNAP-II shortly after initiation. The 
recruitment of the kinase activity of cdk9 in pTEFb to the polymerase phosphorylates not 
only the ser-2 of the CTD of RNAP-II, linking to H3K36 modifications (see Table 2), but also 
the C-terminal region of the Spt5h subunit of DSIF. This releases NELF from the complex 
and converts DSIF into a positively acting elongation factor. DSIF then cooperates with Tat-
SF1 and the mPAF complex to super-charge elongation. The on-going ser-2 phosphorylation 
of the CTD of RNAP-II is associated with histone H2B mono-ubitination of K 120. The FACT 
complex is then recruited to help unwind nucleosomes (Barboric, Lenasi et al. 2009).  
Mammalian polymerase associated factor complex (mPAF) functions in transcription after 
mediator recruits RNAP-II; mPAF helps recruit the histone methylases and possibly RNA 
processing factors to the RNAP-II based on CTD phosphorylation. PAF binds the 
polyadenylation factors at the promoter and transfers them to the elongating polymerase. 
The mPAF subunit parafibromin alters poly(A) site choice by association with CPSF/CstF 
(Rozenblatt-Rosen, Nagaike et al. 2009; Shi, Di Giammartino et al. 2009) and alterations in 
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parafibromin cause tumors. Thus it is clear that pTEFb plays a pivotal role in elongation, 
polyadenylation thru mPAF recruitment, and splicing through the H3K36 modifications. 
4.5 The associations of pTEFb and ELL2 to form the super elongation complex 
Two recent papers have shown that pTEFb can be found in distinct complexes based on cell 
type and HIV status. There are numerous shared proteins between these complexes see 
Table 3, with potential fusion partners of the MLL gene in each complex. A super elongation 
complex (SEC) was demonstrated in 293, a human embryonic kidney derived cell line 
generated by adenovirus DNA transformation; the 293 line shares many properties with 
neuronal cells (Shaw, Morse et al.). The SEC was isolated (Lin, Smith et al. 2010) using 
antibody-mediated purification of epitope-tagged MLL-ELL1, MLL-ENL, MLL-AFF1 or 
MLL-AF9 transfected into the cells, with subsequent analysis of the immune-precipitate by 
mass spectrometry. The complexes all contained: cdk9, cyclin T1, T2a and b; AFF1, AFF4, 
AF9, ENL, and an ELL gene product, 1, 2 or 3. If the AFF4 was used for the pull-down EAF1 
and all three ELLs were present. If epitope-tagged ELL1 or ELL2 was used for the pull-
down the other was found in the complex, perhaps implying mixed dimers, while if ELL3 
was used for the pull-down ELL1 but not ELL2 was found. With antibodies to tagged ELL1, 
no EAF was found while if ELL2 or ELL3 was used EAF1 and 2 were co-immuno-
precipitated in the complex. This variety indicates that there may be several different 
complexes based on which ELL is expressed in the cells. What emerges is that the AFF4 is 
crucial for the formation of the SEC and recruitment to the HSP70 both at the promoter and 
into the body of the gene during transcription (Lin, Smith et al. 2010). Those studies did not 
address the recruitment of the pTEFb in the SEC from the 7SK:hexim complexes. This is an 
area that will be of interest in the future. Our ChIP experiments, outlined in Figure 3,  
 
Major MLL 
fusion 
partners 
 
(Meyer, 
Kowarz et al. 
2009) 
Super 
elongation 
complex 
components
 
(Lin, Smith 
et al. 2010) 
DotCom 
components
 
(Mohan, 
Herz et al. 
2010) 
TAR:TAT 
interacting 
complex 
 
(He, Liu et al. 
2010) 
Up-regulated 
in plasma cells 
 
(Martincic, Alkan et 
al. 2009) 
AFF1/AFF4 AFF4 - AFF4 AFF1  
ELL1 ELL1, 2 or 3 - ELL2 ELL2 
EPS15/AF1P - - AFF1  
MLLT1/ENL ENL ENL ENL ENL 
MLLT3/AF9 AF9 AF9 AF9  
MLLT4/AF6 - - -  
MLLT6/AF17 AF17 AF17 -  
MLLT10/AF10 AF10 AF10 -  
SEPT6 - -  
 EAF1 or 1+2 EAF2 EAF2 
 Cdk9 Cdk9 Cdk9 
 Cyclin T Cyclin T Cyclin T 
 PC4/ sub1 
    
Supt5h/  suppressor 
of Ty5 
Table 3. Potential transcription elongation factors implicated in each process or complex. 
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showed that DRB treatment to inactivate pTEFb and ser-2 phosphorylation of the CTD 
eliminated the binding of ELL2 and CstF-64 to the TATA region of Igh. In the light of the 
discovery of the SEC this indicates that pTEFb and ELL2 and all of the SEC components may 
be associated in plasma cells as they are in 293 cells. 
In HIV infection of T cells, the rate limiting step for transcription is RNA polymerase 
pausing on viral genes near the 5’ end of all viral transcripts in the Long Terminal Repeat 
(Peterlin and Price 2006). The pause in transcription is relieved by the action of the HIV-1 
Tat protein that recruits the host pTEFb to the TAR element in the viral RNA. TAR is a stem-
loop structure near the 5’ end of the LTR that resembles the 7SK RNA and may thus serve as 
a binding site for pTEFb recruitment. Epitope tagged factors cdk9-F and inducible 
expression of Tat-HA were used for sequential affinity purifications of proteins (He, Liu et 
al. 2010) and (Sobhian, Laguette et al. 2010). Associated with pTEFb and Tat were AFF4, 
ENL, AF9, and ELL2, summarized in Table 3. These complexes are similar to the SEC but 
differ as well. In the absence of Tat, AFF4 can mediate the ELL2 to pTEFb interaction but 
less efficiently than with Tat present. This is consistent with the SEC studies where AFF4 
seems to be the core of the complex. AFF17 and 10 were not found in the Tat mediated 
complex and ELL1 was missing; AFF17 and 10 may serve the role that Tat does in holding 
the SEC together. ELL2 may be more likely to associate when Tat is present than when 
AFF17 or 10 are part of the complex. The over-expression of Tat or AFF4 seem to use a 
common mechanism to stabilize ELL2 which  is mediated by the cdk9 kinase activity of 
pTEFb and the sequestration of ELL2 in the complex to block proteolysis. Whether ELL2 is a 
substrate for pTEFb phosphorylation has not yet been determined but ELL2 shows a 
mobility shift in the experiments. 
Another interesting observation was that the ELL2:pTEFb complexes were associated with a 
number of cellular promoters,  in the absence of TAT:TAR  (He, Liu et al. 2010). This implies 
that the complex is able to enhance the regulation of elongation on many promoters. This 
has implications for the role of ELL2 in regulating plasma cell genes besides Igh, for 
example, it could enhance the expression of IRF-4 and blimp-1, thus solidifying their 
expression and the plasma cell phenotype. 
5. Role of ELL2 in Igh expression and alternative RNA processing 
5.1 ELL2 is induced and binds to the Igh TATA region in plasma cells 
The mRNA for ELL2 has been shown to be induced at least 4 to 6-fold in plasma cells when 
compared to B-cells by micro-array analyses by several labs (Underhill, George et al. 2003) 
and (Turner, Mack et al. 1994; Lin, Wong et al. 1997). We showed that both a 59 kDa 
cleavage product of full length ELL2 protein and a shorter, internal Methionine (M186) 
initiated 58kDa form of ELL2 were increased in plasma cells and after stimulation of splenic 
B-cells to Igh secretion (Martincic, Alkan et al. 2009). Taken together these data suggest an 
important role for ELL2 in Igh chain expression. 
The mRNA and protein for ELL2 increase when Ig sec mRNA production increases and 
ELL2 is decreased with over-express hnRNP F; over-expression of hnRNP F decreases 
production of Igh sec mRNA (Martincic, Alkan et al. 2009). By chromatin 
immunoprecipitations,  ELL2 is associated with the endogenous Ig mu heavy chain gene in 
primary mouse splenic B cells and with the gamma Igh in cultured mouse B and plasma 
cells. An siRNA to ELL2 is able to diminish Ig secretory mRNA production not only of Ig 
gamma in cultured plasma cells, but also of Ig mu in primary splenic B cells. That same 
siRNA to ELL2 is able to inhibit the binding of not only itself but also of CstF-64, a factor in 
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the poly(A) addition reaction, to the promoter of an Igh gene transfected into J558L plasma 
cells which lack their own Ig gene (summarized in Figure 3).  
Increased phosphorylation of both ser-5 and ser-2 on the CTD of RNAP-II and loading of 
polyadenylation factors and ELL2 onto the polymerase at the promoter in plasma cells vs B-
cells (see Figure 3) contribute to regulation of production of Igh mRNA (Shell, Martincic et 
al. 2007). RNAP-II is therefore more competent to deliver the factors to the first poly(A) site 
encountered, the sec-poly(A) site in plasma cells. Hence, in the absence of the competing 
factors that would be both negative for the sec poly(A) site and positive for splicing, and 
with higher local concentrations of CstF and CPSF, the polyadenylation reaction could be 
favored over splicing by mass-action. How do the polyadenylation factors load better in 
plasma cells? We hypothesize that the polyadenylation factor loading onto RNAP-II is 
directed at least in part by ELL2 in its association with pTEFb and subsequent mPAF 
interactions. 
5.2 ELL2, but not ELL1 or PC4, influences the sec poly (A) site choice in Igh reporters 
We had previously cloned the ~11 kb IgGb heavy chain gene with an intact Ig heavy chain 
promoter, introns and enhancer between VDJ and CH1; production of B- or plasma cell 
specific Igh sec vs membrane forms of mRNA was shown to be dependent on the cell-type 
with this reporter (Kobrin, Milcarek et al. 1986). The Igh gene was co-transfected into A20 B-
cells along with an empty expression vector or full length cDNAs for ELL2, ELL1, CstF-64 or 
PC4 cloned into that vector. We also assessed the effect of NH2 terminal, COOH terminal 
portions of ELL2 and a mutant in which the M 133, 138, 186 were changed to Ileu to prevent 
internal translational initiation. The ratio of sec (polyadenylated at first site): mb (splicing to 
M1) heavy chain mRNA species produced in these cells after 48 hours was quantified by 
QPCR following RT using the primers specific for sec p(A) site use or splicing. The data are 
summarized in Figure 6, below. Equal efficiency of transfection by the ELL1 & 2, CstF-64 
and PC4 plasmids was assessed by RT-QPCR of their mRNAs using primers unique for the 
transfected products.  
Considering the sec:mb mRNA ratio produced by the IgG2b heavy chain reporter in the B-
cells as 1, we saw, in the data summarized in Figure 6, an increase in secretory specific 
mRNA production of approximately 4.5-fold when A20 B cells were transfected with mRNA 
for wild-type ELL2. This stimulation of secretory mRNA is more efficient with ELL2 than 
co-transfection with CstF-64, shown previously to drive first site poly(A) selection in 
chicken DT-40 cells (Takagaki, Seipelt et al. 1996). A dominant negative mutation of CstF-64 
(d/n), which can assemble into the CstF complex but lacks the essential final 282 a.a.s at the 
COOH domain, suppressed sec poly (A) site use, as we predicted. Co-transfection of the Igh 
reporter and shRNA plasmid targeted to ELL2 expression (iELL2) reduced production of the 
Igh secretory form while a nonsense shRNA (nsiRNA) had no effect. 
When cells were transfected with a plasmid carrying engineered ELL2 with Met 133, 138 
and 186 to Ileu mutations, (see Figure 5 for location of the in-frame methionines) the 
production of Ig secretory mRNA was still stimulated relative to empty vector, about 4-fold. 
These cells would presumably be making primarily full length ELL2 protein and the cleaved 
59 kDa form but not the 58 kDa internally initiated form. Using a clone with a segment of 
ELL2 corresponding to only the amino-terminal (NH2) or the 58 kDa protein (COOH ELL2), 
we observed virtually no stimulation in the production of the secretory specific Ig heavy 
chain mRNA over that with empty vector in B-cells. Taken together the data indicate that 
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Fig. 6. ELL2 stimulates sec mRNA production. A reporter containing the intact Igh locus 
with promoter and enhancer and normal sec poly(A) site in competition with M1 splice (see 
Figure 2) was transfected into A20 B-cells along with the indicated expression vector (pEF4) 
containing either no insert (empty vector), portions of ELL2 , the full wt. ELL2, an ELL2 
where the methionine at M 133, 138 and 185 was substituted with Isoleucine so they could 
not internally initiate, ELL1, PC4, CstF-64, a dominant negative (d/n)  form of CstF-64 that 
can inhibit action of the CstF trimer, or with a vector containing siELL2 or non-specific 
siRNA. The output of poly(A)+ mRNA either secretory or mb specific was assessed by 
QPCR using probes outlined in Figure 2.  The asterisk * indicates P=<0.05 indicating a 
different from the empty vector as a control using ANOVA and a Tukey’s post-test. Data 
adapted and simplified from (Martincic, Alkan et al. 2009). 
the wild type, full length  form of ELL2 is the most efficient at stimulating secretory-specific 
mRNA production from the Igh reporter. We speculate that the increased production of full 
length ELL2 results in rapid turnover into the 59/58kDa forms after having had its effect on 
Igh poly(A) splicing choice. Some of the ELL2 could be stabilized in the complex with 
pTEFb as it is in the TAT:TAR  complex during HIV infection.  
Meanwhile, full length ELL1 was unable to stimulate secretory specific mRNA production, a 
surprising result in light of the similarities of the sequences of the two proteins and their 
role at enhancing elongation. With PC4, a co-transcriptional factor with multiple activities 
(Calvo and Manley 2005) and (Garcia, Rosonina et al. 2010), there was also no stimulation of 
sec-specific mRNA production, even though we showed that PC4 bound to the Igh 
promoter in plasma cells.  
5.3 ELL2 influences splicing of alternative exons with several promoters 
To assess the effects of elongation factors on splicing we used transient transfections with 
the alternative splicing constructs (Kornblihtt, De La Mata et al. 2004) with the ED1 exon 
driven by the alpha-globin promoter. This reporter has been used extensively to study the 
role of elongation on splicing. First we used the alpha-globin promoter to drive transcription 
and saw an effect of ELL2 on splicing (see Table 4). Then we cloned in the J558 Igh promoter 
and enhancer to replace the alpha-globin promoter in the reporter to control for potential 
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promoter effects. We used RT QPCR to assess ED exon inclusion or skipping in A20 B-cells. 
As summarized in Table 4, we saw significant increases in skipping with ELL2 (P<0.001) vs 
the vector control. ELL1 had a 2 to 4 fold effect on skipping (with P<0.05). The COOH 
portion of ELL2 (aka 58 kDa ELL2, amino acids 186-640) was effective at the splicing choice 
and this may reflect a role for it in the plasma cell. We saw a greater effect with the NH2 
terminal end (aa 1-285) than the whole ELL2 molecule on the alpha-globin-promoter driven 
splicing reporters but not the Ig promoter constructs. This reveals differences in the two 
reactions and could indicate a role for interactions of the promoter, other factors, or the 
RNAP-II with portions of ELL2.  
 
 Fold increase over control 
 
ELL2 
(aa 1-640) 
ELL2 NH2
(aa 1-285) 
ELL2 
COOH 
(aa 186-640) 
 
ELL1 
Igh sec poly(A) site> splicing 
(Igh promoter) 
4.5 - - - 
Exon skipping with Igh 
promoter 
3 - 3 3 
Exon skipping with alpha-
globin promoter 
3 6 4 2 
Proximal poly(A) site choice 
(400 nts bw sites) 
- - - - 
Proximal poly(A) site choice 1 
kb spacing 
3 - 4.5 Not done 
Table 4. Summary of transfection experiments with ELLs 
Meanwhile we saw no effects on poly(A) choice with ELL2 or ELL1 in B cells where tandem 
poly(A) sites were only about 400 nts apart in the reporter (Table 4). In the Igh gene the two 
poly(A) sites (sec vs mb) are ~3kb apart. When the sites were moved >1kb apart in our 
polyadenylation only vector, full length ELL2 stimulated proximal poly(A) site use.  
Interestingly the fraction of ELL2 from aa 186 to 640 amino-acids was better than the full 
length molecule. ELL1 was not tested in this assay but should be for completeness. Thus 
various portions of the ELL2 have different activities. It will be important to determine 
which of the components of the SEC or TAT:TAR complex interact directly with which 
portions of ELL2. Yeast two-hybrid studies with cloned portions of the ELL2 molecule are in 
progress to determine this. The region corresponding to the occludin-like and p53 
interacting domain shows trans-activation by itself, indicating that it interacts with the basal 
transcription machinery in yeast. 
6. Insights from viral systems 
Other model systems for poly(A) site use  include  virus infection. In adenovirus distal 
poly(A) sites in the major late transcript are favored later in infection (DeZazzo, Falck-
Pedersen et al. 1991); is this because the levels of polyadenylation factors and elongation 
factors fall?  This has not been explored. It would be interesting to examine the levels of the 
subunits of the SEC both in the differentiated cells and late in viral infection. The prediction 
would be that they decline leading to pauci-polymerases with little ability to polyadenylate 
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efficiently. Perhaps a similar situation pertains late in development of a particular tissue, a 
kind of elongation exhaustion. 
The ICP4 gene of Herpes Simplex Virus Type 1 (HSV-1) targets TFIID, a general transcription 
factor bound at the promoter (Grondin and DeLuca 2000) to high-jack transcription towards  
viral genes.  ICP4 forms complexes with TFIID and mediator (Lester and DeLuca 2011). The 
prediction would be that the presumed association of the polyadenylation factors with TFIID 
would allow the HSV genes to associate with mPAF and the elongation factors more 
efficiently. In addition another HSV gene, ICP27, mediates the inhibition of cellular splicing 
early in infection, whereas, later it helps to recruit cellular RNA polymerase II to viral 
replication sites and to facilitate viral RNA export (Sandri-Goldin 2008). Early on, ICP27 
specifically mediates the reduction of phosphorylation of cellular  SR proteins  and thereby 
changes their subcellular location; this favors viral mRNA production  (Sciabica, Dai et al. 
2003). Phosphorylation of SR proteins has been shown to influence RNA binding and is 
variable based on physiological changes  (Ghosh, Adams et al. 2011). What if any changes may 
occur in the phosphorylation of SR proteins during B cell maturation has not been explored. 
An earlier discussion of the HIV-1 TAT:TAR interaction with components of the SEC shows 
how viruses can help us clearly get at molecular events in elongation. In HIV-1 the long 
terminal repeat RNA contains not only the TAR stem loop, for TAT association, but also a 
poly(A) site followed by a major splice donor. This arrangement of sites is repeated at the 3’ 
end of the virus where the poly(A) site functions. The promoter proximal poly(A) site is 
occluded  by the presence of the major splice donor (Ashe, Griffin et al. 1995) and the U1 
RNA binding there at the splice donor plays a role in the occlusion  (Ashe, Furger et al. 
2000). In addition there is a gene loop structure that is found between the 5′LTR promoter 
and 3′LTR poly (A) signal. An inhibitor of pTEFb (flavopiridol) blocks 5′ to 3′LTR 
juxtaposition, indicating that this structure is maintained during transcription. Activation of 
the 5′LTR poly (A) signal or inactivation of the 3′LTR poly (A) signal abolishes gene loop 
formation.  Thus transcription, elongation factors,  and pre-mRNA processing are essential 
for gene loop formation (Perkins, Lusic et al. 2008). The prediction is that these structures 
represent a defining feature of regulation for the virus. It has been suggested that the 
transcription factory for cellular genes stays put while the DNA and RNA thread through. 
The role of elongation factors in formation of this structure is unknown. 
7.1 Model for regulated alternative RNA processing in the Igh gene 
In Figure 7 a model for what we know about Igh alternative mRNA processing is presented. 
In B-cells, U1A (Milcarek, Martincic et al. 2003), hnRNP F (Veraldi, Arhin et al. 2001), and 
Serine-Arginine-rich (SR) proteins like ASF/SF2  (Bruce, Dingle et al. 2003) are expressed in 
relatively higher concentrations than in plasma cells. The CTD of RNAP-II on the Igh gene is 
relatively under-phosphorylated; the polyadenylation factors CPSF and CstF and ELL2 are 
not strongly associated (Shell, Martincic et al. 2007) with the polymerase. The question mark 
indicates that we do not know if enhancing SR protein(s) like SF2/ASF for the 5’ splice to 
the M1 exon is/are associated with the RNAP-II. When the secretory-specific poly(A) site is 
transcribed there are few polyadenylation factors on RNAP-II to recognize it (thus it is a 
pauci-polymerase). In B-cells splicing between the 5’ splice site in the terminal (CH3 in 
gamma, CH4 in mu) exon, occurs presumably as the default pathway. This leads to the 
production primarily but not exclusively of the membrane-specific form of the Igh mRNA 
and protein at a low level. (Some sec mRNA is made at a low level.) 
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Fig. 7. Model for the use of the splice site to M1 in B cells and the sec poly(A) site in plasma 
cells, mediated by elongation factors like ELL2, part of the SEC.  
In plasma cells the RNAP-II is more heavily phosphorylated early on, perhaps by cyclin C 
and cdk8, perhaps through the action of NF-kB, and RNAP-II is associated with the 
polyadenylation factors and ELL2 via the associated pTEFb kinase activity. Polyadenylation 
factors are also associated with the polymerase, perhaps through the action of mPAF. When 
the RNAP-II reaches the sec poly(A) site the factors act upon the pre-mRNA and trigger 
production primarily but not exclusively of the sec-specific mRNA. This is an efficient 
process and mRNA yield per polymerase pass is much higher. The splice to M1 cannot then 
occur on the cleaved RNA; the CH3 exon splice to M1 is thus “undefined” by either an 
active or passive mechanism. 
7.2 Questions remaining 
Since the secretory poly(A) site occurs first in the Igh transcript, how is membrane-specific 
Igh mRNA ever made? We know that the levels of U1 snRNP splice factor and Serine 
Arginine (SR) exon enhancing factors are higher in B-cells than in plasma cells. This could 
facilitate stronger 5’ splice site recognition. In B-cells ELL2 levels are lower and the RNAP-II 
is quite deficient in polyadenylation factors. U1A and hnRNP F block access to the poly(A) 
site as well (Phillips, Pachikara et al. 2004; Ma, Gunderson et al. 2006) & (Veraldi, Arhin et 
al. 2001). The sec-poly(A) site is therefore weakest in B-cells and used less than half the time. 
As a result, some RNAP-IIs ignore it and proceed downstream the 3 kb to the membrane 
poly(A) site. The long intron (~3 kb) allows the setting up of the weak 5’ splice site in CH3 
with its associated enhancing factors on the pre-mRNA.  Meanwhile the RNAP-II may have 
acquired polyadenylation factors in the IVS between CH3 and M1, ‘on the fly’ as it were, as 
is seen for the c-myc and GAPDH genes (Glover-Cutter, Kim et al. 2008). Acquisition of 
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polyadenylation factors by the polymerase ‘on the fly’ may be a less efficient process and 
could account for the overall reduced amount of processed Igh transcript seen in B-cells. 
This may explain the pause seen in some studies after the secretory poly(A) site in both B 
cells and plasma cells (Peterson, Bertolino et al. 2002), and listed  in Table 1. In the case of B 
cells perhaps the polyadenylation factors are added to RNAP-II at the pause, although at a 
sufficiently low level so that we were not able to see them in our chromatin IP studies. In 
plasma cells the polymerase may pause to allow time for the polyadenylation reaction to 
occur. In vitro a coupling between splice sites and poly(A) sites has been seen which may 
slow the polymerase down (Rigo and Martinson 2008) and this may explain the pause. The 
poly(A) site at the last membrane-encoding exon is known to be a strong default site but the 
RNAP-II must be competent for processing the RNA when it reaches it.  Some transcripts 
probably never get processed at all and turn-over rapidly in the nucleus. 
Is the skipping of the 5’ splice site in CH3 an active or passive process and are SR proteins 
involved?  The increase of SRp20 levels in plasma cells suggests that the splicing inhibitory 
process of this SR protein may play a significant role. It is not known if it travels with the 
RNAP-II complex in plasma cells or associates with the nascent RNA. This remains an 
interesting and open question. 
What role does histone modification play in directing polyadenylation?  The increase in ser-
5 and ser-2 near the Igh promoter should be accompanied by increases in H3 K4, K36 and 
perhaps K79 methylations. This is another open question in the regulation of the alternative 
processing of Igh RNA. 
An additional question is what is the role of ELL2 vs ELL1 in the splicing vs 
polyadenylation choice. Both ELL2 and ELL1 direct exon skipping with an alpha-globin or 
the Igh promoter (Table 4). When we assessed the ability of the “COOH” portion of ELL2 
(aa 186-640) in the Igh reporter assay it had minimal effect on first poly(A) site use. However 
that protein was lacking the first 186 amino-acids encompassing one region thought to 
interact with the mediator complex (aa168-186) as well as the EAF2 interaction region  (aa 6-
80). Therefore we hypothesize that when ELL2 was enhancing the choice of the sec poly(A) 
site it might have been acting as a bridge between several factors. This is in keeping with 
two regions of ELL2 interacting with either different mediator subunits or EAF1 . Hence 
maintaining proper spacing may be key. It will be interesting to determine what proteins 
uniquely interact with ELL1 versus ELL2. Perhaps they are AF17 and AF10, see Table 3. 
A major issue for plasma cell development is whether ELL2 drives the expression of other 
genes besides Igh. In the TAT:TAR studies ELL2 was found on several promoters by 
chromatin IP. Our preliminary data support a more broad distribution of ELL2 on plasma 
cell genes. If ELL2 acts independently of the Igh promoter it may assist the expression of 
IRF4 and blimp-1, thus providing a feed-forward loop for its own expression. More IRF4 
would lead to more ELL2 which would lead to more IRF4 and so on. Global genome wide 
mapping of ELL2 binding would help to reveal its targets. Knocking ELL2 out in a 
conditional way so the animals survived would also help show what it was responsible for 
activating in specific cell lineages. These are separate but complementary questions. 
8. Conclusions  
The Igh locus has been a useful model in an important biological system; we have much 
more to learn from it. The experiments done thus far on the role of elongation in directing 
poly (A) site use and choice provide us with worth-while glimpses of how RNAP-II 
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functions with a myriad of other factors to produce large amounts of mature mRNA. The 
interactions of these complexes with the specific modifications of the CTD of RNAP-II may 
only be able to be approached by in vitro methodologies as was done for the interactions of 
SET2 with phosphorylated CTD (Vojnic, Simon et al. 2006). The role of individual factors 
like ELL2 may have some redundancy with other elongation factors but the observation that 
portions of ELL1 and 2 differ in primary sequence permit us to consider that each factor 
may play a unique role in gene expression. The additive effect of all the factors in a single 
complex (SEC) implies they are all needed. The immune system is particularly suited to the 
study of conditional knock-outs targeted specifically at B-cell or T-cells. Knocking out ELL2 
specifically in the B-cell lineage should provide valuable insights into its role in elongation 
and Igh mRNA processing. Once we fully understand how polyadenylation is linked to 
transcription we may then be able to more easily see how the competition between splicing 
and polyadenylation can be accomplished.  
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